Pulse Biosciences announces long-term clinical data for nPulse Vybrance percutaneous electrode System in benign thyroid nodule ablation 71314. Posted on March 10, 2026 at 12:10 am (GMT+8) Pulse Biosciences, Inc. announces positive clinical data for nPulse(TM) System in benign thyroid nodule ablation. Hayward, CA, March 9, 2026 - Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, has released new clinical data demonstrating highly favorable outcomes for its proprietary nPulse(TM) System in the ablation of benign thyroid nodules. This development marks a potentially significant milestone in the company's trajectory and may have material implications for investors and the company's share price. Key highlights from the report. * 100% Patient-Reported Cosmetic Satisfaction: All patients in the study were "Highly Satisfied" with the cosmetic results at the final follow-up. * 95% Patient-Reported Overall Satisfaction: An overwhelming majority of patients (95%) reported being "Highly Satisfied" with their overall treatment outcome at the final follow-up. * No Serious Adverse Events: The study reported zero serious adverse events, suggesting a favorable safety profile for the nPulse(TM) System. * No Intranodular Fibrosis Detected: Ultrasound assessments conducted between 15-22 months post-procedure showed no evidence of intranodular fibrosis, a critical concern in thyroid ablation procedures. * Potential for Clinical Durability: The absence of intranodular fibrosis and the high satisfaction rates hint at the potential for long-term durability and effectiveness of the treatment. Details for shareholders and potential price-sensitive information. * First-of-Its-Kind Study: The clinical data on benign thyroid nodule ablation positions Pulse Biosciences at the forefront of non-thermal ablation technology. The nPulse(TM) System utilizes nanosecond pulses of electrical energy to clear targeted cells while sparing adjacent non-cellular tissue, differentiating it from thermal ablation techniques. * Market Expansion Potential: The company is actively developing the nPulse(TM) technology not only for thyroid nodules but also for the treatment of atrial fibrillation and other soft tissue ablation markets. This diversification could open significant new revenue streams if clinical success translates into regulatory approval and commercial adoption. * Competitive Advantage: The nPulse(TM) System's ability to deliver non-thermal ablation with high satisfaction and safety may give Pulse Biosciences a strong competitive position versus traditional thermal ablation and surgical options. * No Indication of FDA Approval Yet: While the results are positive, investors should note that the report does not mention regulatory approval for commercial use in the U.S or elsewhere. The news relates to clinical data, which, although promising, is an early step towards market adoption. * Press Release and Further Communication: The company has issued a press release (Exhibit 99.1) to publicize these results, signaling its intent to communicate the significance of this data to the market and stakeholders. About Pulse Biosciences, Inc. Pulse Biosciences is committed to health innovation through bioelectric medicine. The company's proprietary nPulse(TM) technology delivers nanosecond pulses of electrical energy to non-thermally clear targeted cells. The company is developing nPulse for use in atrial fibrillation and other surgical soft tissue ablation indications, aiming to improve patient outcomes and provider workflows. The company owns several trademarks, including nPulse(TM), Vybrance(TM), CellFX(TM), Nano-Pulse Stimulation(TM), NPS(TM), nsPFA(TM), and others. Forward-Looking statements. Pulse Biosciences has cautioned that any statements regarding early clinical successes, future regulatory approval, commercialization, or competitive position are forward-looking and subject to risks and uncertainties. The company reminds investors that actual outcomes may differ materially from current expectations and that there is no guarantee of future regulatory approval or market adoption. Investors are urged to review the company's filings with the SEC for further information on these risks. Contact information. * Investors: Jon Skinner, CFO - [email protected] * Media/Analyst Relations: Gilmartin Group, Philip Trip Taylor - [email protected], 415.937.5406 Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The forward-looking statements herein are based on current information and expectations, which are subject to change without notice.

Pulse Biosciences has established a new at-the-market equity programme with TD Securities, allowing the company to sell up to $60 million of common stock in at-the-market transactions. The agreement was signed on 19 February 2026, one day after terminating a previous programme with approximately $60 million in unused capacity. The company is not obligated to sell shares and can suspend offers at its discretion. TD Cowen will receive up to 3% commission on gross sales. The arrangement effectively rolls over unused capacity from the previous programme, preserving flexible funding options whilst maintaining access to incremental capital without committing to a specific financing timeline. The structure provides Pulse Biosciences with a refreshed equity financing channel to support ongoing activities and potential growth initiatives, though actual usage will depend on market conditions and management decisions.

Pulse Biosciences to present at the 44th Annual J.P. Morgan Healthcare Conference. HAYWARD, Calif. - (BUSINESS WIRE) - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse(TM) technology using its proprietary Nanosecond Pulsed Field Ablation(TM)(nanosecond PFA or nsPFA(TM) energy, today announced plans to present at the upcoming 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Pulse Biosciences' Management is scheduled to present on Wednesday, January 14, 2026, at 3:45pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences(R) Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary nPulse(TM) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Investors: Pulse Biosciences, Inc. Jon Skinner, CFO [email protected]